Abstract:Context: Immune-oncology strategies are revolutionising the perioperative treatment in several tumour types. The perioperative setting of renal cell carcinoma (RCC) is an evolving field, and the advent of immunotherapy is producing significant advances. Objective: To critically review the potential pros and cons of adjuvant and neoadjuvant immune-based therapeutic strategies in RCC, and to provide insights for future research in this field. Evidence acquisition: We performed a collaborative narrative review of the existing literature. Evidence synthesis: Adjuvant immunotherapy with pembrolizumab is a new standard of care for patients at a higher risk of recurrence after nephrectomy, demonstrating a disease-free survival and overall survival benefit in the phase 3 KEYNOTE-564 trial. Current data do not support neoadjuvant therapy use outside clinical trials. While both adjuvant and neoadjuvant immune-based approaches are driven by robust biological rationale, neoadjuvant immunotherapy may enable a stronger and more durable antitumour immune response. If neoadjuvant single-agent immune checkpoint inhibitors demonstrated limited activity on the primary tumour, immune-based combinations may show increased activity. Overtreatment and a risk of relevant toxicity for patients who are cured by surgery alone are common concerns for both neoadjuvant and adjuvant strategies. Biomarkers helping patient selection and treatment deintensification are lacking in RCC. No results from randomised trials comparing neoadjuvant or perioperative immune-based therapy with adjuvant immunotherapy are available. Conclusions: Adjuvant immunotherapy is a new standard of care in RCC. Both neoadjuvant and adjuvant immunotherapy strategies have potential advantages and disadvantages. Optimising perioperative treatment strategies is nuanced, with the role of neoadjuvant immune-based therapies yet to be defined. Given strong biological rationale for a pre/perioperative approach, there is a need for prospective clinical trials to determine clinical efficacy. Research investigating biomarkers aiding patient selection and treatment deintensification strategies is needed. Patient summary: Immunotherapy is transforming the treatment of kidney cancer. In this review, we looked at the studies investigating immunotherapy strategies before and/or after surgery for patients with kidney cancer to assess potential pros and cons. We concluded that both neoadjuvant and adjuvant immunotherapy strategies may have potential advantages and disadvantages. While immunotherapy administered after surgery is already a standard of care, immunotherapy before surgery should be better investigated in future studies. Future trials should also focus on the selection of patients in order to spare toxicity for patients who will be cured by surgery alone.

Game of thrones: immunotherapy versus molecular targeted therapy in renal cell cancer scenarios

Recent pharmacological approaches for the treatment of renal cell carcinoma

Current Treatment Options for Renal Cell Carcinoma: Focus on Cell-Based Immunotherapy

Immunotherapy for renal cell carcinoma: New therapeutic combinations and adverse event management strategies: A review

Current and emerging therapies for first line treatment of metastatic clear cell renal cell carcinoma

Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma

Immunomodulatory therapies for renal cell carcinoma.

Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma

Approaches to Treating High Risk and Advanced Renal Cell Carcinoma (RCC): Key Trial Data That Impacts Treatment Decisions in the Clinic

Targeted therapy of metastatic renal cell carcinoma

Immunotherapeutic Innovations in Clear Cell Renal Cell Carcinoma: Current Strategies and Future Directions

Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma

Immunotherapy of Clear-Cell Renal-Cell Carcinoma

Advances in immunotherapy of metastatic renal cell carcinoma

Combination of immune checkpoint inhibitors and tyrosine kinase inhibitors for the treatment of renal cell carcinoma

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)

Established and emerging biomarkers of immunotherapy in renal cell carcinoma

Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas

Adjuvant therapy in renal cell carcinoma: Tyrosine kinase inhibitor versus immune checkpoint inhibitor

Neoadjuvant and Adjuvant Immune-based Approach for Renal Cell Carcinoma: Pros, Cons, and Future Directions

Treatment Landscape of Renal Cell Carcinoma